Theoretically yes. A lot of hurdles to get above $

Theoretically yes. A lot of hurdles to get above $1 and will likely depend on the partnership deal. It can be literally overnight. If the BE studies go well, which I am very confident then a partner would probably jump in for the whole thing because it is modular.

Basically you are just adding the naltrexone beads to the opioid beads. They would look identical. So if one works, which has previously passed PH2, then it likely works for all.

Also will depend on the ANDA and NDA products for these current BE studies.  If they are higher revenue products, then we could get there as well as on speculation as to the modular capability.

I even believe we can get to $1 without the ART but it will take longer. This HITK product for a 100m drug is very interesting as well as MIK001 which is obviously being kept very secret and likely for Actavis. Even the HK Pharma product falls in this category.

So many drugs. Basically Elite is becoming what Novel and Epic are now. Plus they have the ART, Pretty obvious really but in the end it will be the ART that blows things up quickly.

Folks have been working this stock awfully hard. Heck Poorme has been posting all weekend and what you are seeing is trading and accumulating large amounts of shares. Why buy at .10, 15, 20 when you can manipulate the stock, play games and buy 3x the number of shares or even more with the same money...